UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout

Journal of rheumatology, 2009-06, Vol.36 (6), p.1273-1282

2009

Volltextzugriff (PDF)

Effects of Febuxostat in Early Gout: A Randomized, Double-Blind, Placebo-Controlled Study

Arthritis & rheumatology (Hoboken, N.J.), 2017-12, Vol.69 (12), p.2386-2395

2017

Volltextzugriff (PDF)

The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial

Arthritis research & therapy, 2010-01, Vol.12 (2), p.R63-R63, Article R63

2010

Volltextzugriff (PDF)

GPNMB augments Wnt-1 mediated breast tumor initiation and growth by enhancing PI3K/AKT/mTOR pathway signaling and β-catenin activity

Oncogene, 2019-06, Vol.38 (26), p.5294-5307

2019

Volltextzugriff (PDF)

Randomized Controlled Trial of Febuxostat Versus Allopurinol or Placebo in Individuals with Higher Urinary Uric Acid Excretion and Calcium Stones

Clinical journal of the American Society of Nephrology, 2013-11, Vol.8 (11), p.1960-1967

2013

Volltextzugriff (PDF)

Considering social values in the seafood sector using the Q-method

Marine policy, 2015-02, Vol.52, p.68-76

2015

Volltextzugriff (PDF)

Febuxostat Compared with Allopurinol in Patients with Hyperuricemia and Gout

The New England journal of medicine, 2005-12, Vol.353 (23), p.2450-2461

2005

Volltextzugriff (PDF)

Glycoprotein Nonmetastatic B Is an Independent Prognostic Indicator of Recurrence and a Novel Therapeutic Target in Breast Cancer

Clinical cancer research, 2010-04, Vol.16 (7), p.2147-2156

2010

Volltextzugriff (PDF)

The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age

BMC geriatrics, 2012-03, Vol.12 (1), p.11-11, Article 11

2012

Volltextzugriff (PDF)

Effect of Prophylaxis on Gout Flares After the Initiation of Urate-Lowering Therapy: Analysis of Data From Three Phase III Trials

Clinical therapeutics, 2010-12, Vol.32 (14), p.2386-2397

2010

Volltextzugriff (PDF)

Renal function in gout: long-term treatment effects of febuxostat

Journal of clinical rheumatology, 2011-01, Vol.17 (1), p.7-13

2011

Volltextzugriff (PDF)

Febuxostat in gout: serum urate response in uric acid overproducers and underexcretors

Journal of rheumatology, 2011-07, Vol.38 (7), p.1385-1389

2011

Volltextzugriff (PDF)

Preservation of Renal Function during Gout Treatment with Febuxostat: A Quantitative Study

Postgraduate medicine, 2013-01, Vol.125 (1), p.106-114

2013

Volltextzugriff (PDF)

Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: A 28‐week, phase III, randomized, double‐blind, parallel‐group trial

Arthritis and rheumatism, 2008-11, Vol.59 (11), p.1540-1548

2008

Volltextzugriff (PDF)

African American patients with gout: efficacy and safety of febuxostat vs allopurinol

BMC musculoskeletal disorders, 2012-02, Vol.13 (1), p.15-15, Article 15

2012

Volltextzugriff (PDF)

Outcome domains for studies of acute and chronic gout

Journal of rheumatology, 2009-10, Vol.36 (10), p.2342-2345

2009

Volltextzugriff (PDF)

Effects of Febuxostat in Early Gout

Arthritis & rheumatology (Hoboken, N.J.), 2017-12, Vol.69 (12), p.2386-2395

2017

Volltextzugriff (PDF)

Patient-reported outcomes in chronic gout: a report from OMERACT 10

Journal of rheumatology, 2011-07, Vol.38 (7), p.1452-1457

2011

Volltextzugriff (PDF)

Making good on a call to expand method choice for young people - Turning rhetoric into reality for addressing Sustainable Development Goal Three

Reproductive health, 2017-04, Vol.14 (1), p.53-53, Article 53

2017

Volltextzugriff (PDF)

Women with gout: Efficacy and safety of urate‐lowering with febuxostat and allopurinol

Arthritis care & research (2010), 2012-02, Vol.64 (2), p.256-261

2012

Volltextzugriff (PDF)

Progress in measurement instruments for acute and chronic gout studies

Journal of rheumatology, 2009-10, Vol.36 (10), p.2346-2355

2009

Volltextzugriff (PDF)

Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims

Journal of rheumatology, 2004-08, Vol.31 (8), p.1575

2004

Volltextzugriff (PDF)

Tophus measurement as an outcome measure for clinical trials of chronic gout: progress and research priorities

Journal of rheumatology, 2011-07, Vol.38 (7), p.1458-1461

2011

Volltextzugriff (PDF)

Determinants of the Clinical Outcomes of Gout During the First Year of Urate-Lowering Therapy

Nucleosides, nucleotides & nucleic acids, 2008-06, Vol.27 (6-7), p.585-591

2008

Volltextzugriff (PDF)

Treating Hyperuricemia of Gout: Safety and Efficacy of Febuxostat and Allopurinol in Older Versus Younger Subjects

Nucleosides, nucleotides & nucleic acids, 2011-12, Vol.30 (12), p.1011-1017

2011

Volltextzugriff (PDF)

1 – 25 von 685

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(574)
Mit Volltextzugriff
(531)

Publikationsform

5 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout

Effects of Febuxostat in Early Gout: A Randomized, Double-Blind, Placebo-Controlled Study

The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial

GPNMB augments Wnt-1 mediated breast tumor initiation and growth by enhancing PI3K/AKT/mTOR pathway signaling and β-catenin activity

Randomized Controlled Trial of Febuxostat Versus Allopurinol or Placebo in Individuals with Higher Urinary Uric Acid Excretion and Calcium Stones

Considering social values in the seafood sector using the Q-method

Febuxostat Compared with Allopurinol in Patients with Hyperuricemia and Gout

Glycoprotein Nonmetastatic B Is an Independent Prognostic Indicator of Recurrence and a Novel Therapeutic Target in Breast Cancer

The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age

Effect of Prophylaxis on Gout Flares After the Initiation of Urate-Lowering Therapy: Analysis of Data From Three Phase III Trials

Renal function in gout: long-term treatment effects of febuxostat

Febuxostat in gout: serum urate response in uric acid overproducers and underexcretors

Preservation of Renal Function during Gout Treatment with Febuxostat: A Quantitative Study

Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: A 28‐week, phase III, randomized, double‐blind, parallel‐group trial

African American patients with gout: efficacy and safety of febuxostat vs allopurinol

Outcome domains for studies of acute and chronic gout

Effects of Febuxostat in Early Gout

Patient-reported outcomes in chronic gout: a report from OMERACT 10

Making good on a call to expand method choice for young people - Turning rhetoric into reality for addressing Sustainable Development Goal Three

Women with gout: Efficacy and safety of urate‐lowering with febuxostat and allopurinol

Progress in measurement instruments for acute and chronic gout studies

Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims

Tophus measurement as an outcome measure for clinical trials of chronic gout: progress and research priorities

Determinants of the Clinical Outcomes of Gout During the First Year of Urate-Lowering Therapy

Treating Hyperuricemia of Gout: Safety and Efficacy of Febuxostat and Allopurinol in Older Versus Younger Subjects

Suchergebnisse filtern